Abstract

Aberrant DNA methylation disrupts normal gene expression in cancer and broadly contributes to oncogenesis. We previously developed MethylMix, a model-based algorithmic approach to identify epigenetically regulated driver genes. MethylMix identifies genes where methylation likely executes a functional role by using transcriptomic data to select only methylation events that can be linked to changes in gene expression. However, given that proteins more closely link genotype to phenotype recent high-throughput proteomic data provides an opportunity to more accurately identify functionally relevant abnormal methylation events. Here we present a MethylMix analysis that refines nominations for epigenetic driver genes by leveraging quantitative high-throughput proteomic data to select only genes where DNA methylation is predictive of protein abundance. Applying our algorithm across three cancer cohorts we find that using protein abundance data narrows candidate nominations, where the effect of DNA methylation is often buffered at the protein level. Next, we find that MethylMix genes predictive of protein abundance are enriched for biological processes involved in cancer including functions involved in epithelial and mesenchymal transition. Moreover, our results are also enriched for tumor markers which are predictive of clinical features like tumor stage and we find clustering using MethylMix genes predictive of protein abundance captures cancer subtypes.

Highlights

  • Genomic characterization can elucidate underlying biology, disease etiology and reveal biomarkers of cancer development and progression; each molecular feature is susceptible to different sources of biological and technical measurement noise and provides only one view on the cell state

  • Conducting the first genome wide analysis of epigenome-proteome associations, we present a MethylMix analysis that leverages protein abundance data taking advantage of recent high-throughput proteomic data generated using mass-spectrometry technology to elucidate the role of DNA methylation in cancer

  • Projects for each cancer and their associated data from The Cancer Genome Atlas (TCGA) are in the original Clinical Proteomic Tumor Analysis Consortium (CPTAC) and TCGA cancer site publications: breast cancer: https:// www.nature.com/articles/nature18003#extendeddata (CPTAC) and https://www.nature.com/articles/ nature11412 (TCGA) ovarian cancer: https:// linkinghub.elsevier.com/retrieve/pii/S0092-8674 (16)30673-0 (CPTAC) and https://www.nature. com/articles/nature10166 (TCGA) colorectal cancer: https://www.nature.com/articles/ nature13438 (CPTAC) and https://www.nature. com/articles/nature11252 (TCGA)

Read more

Summary

Introduction

Genomic characterization can elucidate underlying biology, disease etiology and reveal biomarkers of cancer development and progression; each molecular feature is susceptible to different sources of biological and technical measurement noise and provides only one view on the cell state. Comprehensive studies are needed to understand the molecular basis of disease Toward this end a multi-institutional consortium, The Cancer Genome Atlas (TCGA), has extensively characterized numerous cancer sites producing genome wide data for mutations, copy number alterations (CNA), RNA expression, microRNA expression, and DNA methylation [1,2,3,4,5]. Antibody based analysis are inherently limited because of the reduced coverage and inability to compare across proteins due to differential binding effects [6,7] Transcending these limitations, recent advancements in proteomics through high sensitivity mass-spectrometry (MS) are opening new opportunities in cancer research [8]. To accelerate the uptake of proteomics the Clinical Proteomic Tumor Analysis Consortium (CPTAC) is performing proteomic analyses of TCGA tumor bio-specimens for a growing number of tissue types and establishing standardized workflows using high-throughput liquid chromatography tandem mass-spectrometry (LC-MS/MS) to capture the proteome as a whole [6,9,10]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.